Australia's most trusted
source of pharma news
Saturday, 07 June 2025
Posted 2 May 2025 PM
Sanofi has collected a cool AU$17.6 billion (10 billion euros) after closing a deal to sell off a controlling stake in its consumer health business Opella.
US private equity firm Clayton, Dubilier & Rice (CB&R) have a 50 per cent shareholding in Opella while Sanofi still retains a significant stake of 48.2 per cent. Bpifrance takes on a 1.8 per cent stake and will join the Opella Board.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.